Bionomics Limited (BNOX) |
|
2.7 -0.67 (-19.88%)
|
09-29 16:00 |
|
Open: |
3.2 |
Pre. Close: |
3.37 |
|
High:
|
3.56 |
Low:
|
2.7 |
|
Volume:
|
6,850,656 |
Market Cap:
|
22(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:26:16 PM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, downgraded from strong buy. Upward movement continues, but could change at any time. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 5.03 One year: 7.47 |
| Support: |
Support1: 0.93 Support2: 0.77 |
| Resistance: |
Resistance1: 4.31 Resistance2: 6.4 |
| Pivot: |
1.49 |
| Moving Average: |
MA(5): 1.8 MA(20): 1.58
MA(100): 2 MA(250): 3.75 |
| MACD: |
MACD(12,26): 0 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 27.2 %D(3): 16.5 |
| RSI: |
RSI(14): 64.7 |
| 52-week: |
High: 10.89 Low: 0.93 |
| Average Vol(K): |
3-Month: 2,434 (K) 10-Days: 13,119 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BNOX ] has closed below upper band by 5.9%. Bollinger Bands are 210.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.56 - 3.58 |
3.58 - 3.6 |
|
Low:
|
2.66 - 2.68 |
2.68 - 2.7 |
|
Close:
|
2.68 - 2.7 |
2.7 - 2.73 |
|
Company Description |
|
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of social anxiety disorder and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited has a licensing agreement with Merck & Co., Inc. The company was incorporated in 1996 and is based in Eastwood, Australia. |
Headline News |
Fri, 29 Sep 2023
Bionomics (BNOX) Meets Goals in PTSD Study, Stock Rallies 244% - Nasdaq
Thu, 28 Sep 2023
Sharps Technologys Acquisition and Strategic Partnership Propel ... - Best Stocks
Thu, 28 Sep 2023
Healthcare Stocks Moving Up and Down Thursday: BNOX, FEMY, AYTU, AXLA, SPRC, RNLX, SYBX, ACAD - InvestorsObserver
Thu, 28 Sep 2023
Health Care Sector Update for 09/28/2023: BNOX, BOLT, BCLI - Nasdaq
Thu, 28 Sep 2023
Significant Market Movements on September 28 2023 BNOX PTON ... - Best Stocks
Thu, 28 Sep 2023
Analyst Reiterates Positive Outlook on Gamida Cell with Strong Buy ... - Best Stocks
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
8 (M) |
|
% Held by Insiders
|
8.16e+006 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.15 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-346.2 |
|
Return on Assets (ttm)
|
-21 |
|
Return on Equity (ttm)
|
-46.2 |
|
Qtrly Rev. Growth
|
-21.7 |
|
Gross Profit (p.s.)
|
-5.40217e+006 |
|
Sales Per Share
|
3.27174e+006 |
|
EBITDA (p.s.)
|
-1.08315e+007 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-18 (M) |
Stock Valuations |
|
PE Ratio
|
-1.27 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.7 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0.09 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
620440 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
